Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.58 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 8/20 | 0.58 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.57 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16436048 | 0.84 | PTPN1 (0.61) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL2801974 | 0.81 | KCNQ3 (0.85) | P4HTMKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL4740817 | 0.81 | KCNQ3 (0.68) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL3227445 | 0.81 | P4HTM (0.67) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL3064046 | 0.81 | P4HTM (0.67) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL10684470 | 0.79 | PTPN1 (0.88) | PTPN1PTPN6PTPN11KCNQ3KCNQ2 | |
| SCHEMBL9566833 | 0.79 | P4HTM (0.63) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL3817443 | 0.79 | P4HTM (0.63) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL3230527 | 0.78 | CXCR2 (0.63) | P4HTMPTPN1PTPN6PTPN11CXCR2 | |
| SCHEMBL16436052 | 0.78 | KCNQ3 (0.65) | P4HTMPTPN1PTPN6PTPN11CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725775-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-2942346-B1 | PYRIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47415-E1 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-RE47267-E1 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-2942346-A1 | PYRIDINE- AND PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | Syntrix Biosystems, Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981106-B2 | Pyrimidinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748623-B2 | Pyridinecarboxamides as CXCR2 modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | SYNTRIX BIOSYSTEMS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-7151112-B1 | Pharmaceutical uses and synthesis of nicotinamides | UCB SA (GB) | 2006-12-19 | — | — | US | disclosed |
| US-6777432-B1 | TREATING A SUBJECT HAVING AN INFLAMMATORY DISORDER ALLEVIATED BY THE INHIBITION OF GRO- ALPHA CYTOKINES | DARWIN MOLECULAR CORPORATION | 2004-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206647-A1 | PYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS | CXCR2, CXCR1, CXCR3 | P4HTM 1746/4885PTPN1 587/4885PTPN6 668/4885 |
| US-20100210593-A1 | Pyridine- and Pyrimidinecarboxamides as CXCR2 Modulators | CXCR2, CXCR1, CXCR3 | P4HTM 1352/4885PTPN1 344/4885PTPN6 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.